Key result
Nadolol prevents loss of myocardial Na-K-ATPase activity and ouabain binding in canine experimental RHF.
Why the study?
Does nadolol prevent the reduction of myocardial ouabain binding sites and Na-K-ATPase activity in dogs with experimental right-heart failure?
Does nadolol prevent the reduction of myocardial ouabain binding sites and Na-K-ATPase activity in dogs with experimental right-heart failure?
Beta-adrenergic blockade with nadolol prevents the downregulation of myocardial Na-K-ATPase activity and ouabain binding sites in experimental right-heart failure, suggesting a role for heightened sympathetic activity in these changes.
No takes yet. Share an insight, caveat, or question.
Links sympathetic drive to Na-K-ATPase loss in experimental right HF; leaves open clinical translation of beta-blockade.
Fan et al. (1993) studied Right-heart failure. Nadolol vs. Sham-operated dogs and untreated RHF dogs was evaluated on Myocardial ouabain binding sites and Na-K-ATPase activity. Nadolol (40 mg/day) effectively prevented the reduction of myocardial ouabain binding sites and Na-K-ATPase activity that occurred in dogs with experimental right-heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: